|Bid||12.04 x 1000|
|Ask||13.00 x 800|
|Day's Range||12.00 - 12.90|
|52 Week Range||6.35 - 18.00|
|Beta (5Y Monthly)||2.42|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Aug 28, 1996|
|1y Target Est||N/A|
We feel now is a pretty good time to analyse CEL-SCI Corporation's (NYSEMKT:CVM) business as it appears the company...
By John Vandermosten NYSE:CVM READ THE FULL CVM RESEARCH REPORT Upcoming Milestones: ‣ Full review of dataset and safety results ‣Report of selected data from analysis ‣Presentation of results at major oncology conferences ‣Publication of results in journals Third Quarter Fiscal Year 2020 Operational and Financial Results CEL-SCI Corporation (NYSE:CVM) reported its fiscal third quarter 2020
We can readily understand why investors are attracted to unprofitable companies. Indeed, CEL-SCI (NYSEMKT:CVM) stock...